Drooling Flags Severe Dermatomyositis - Summary - MDSpire

Drooling Flags Severe Dermatomyositis

Three cases suggest drooling may mark advanced dermatomyositis with dysphagia, aspiration pneumonia, and poor response to treatment.

  • By

  • Olivia Anderson

  • February 12, 2026

  • 2 min

Share

Objective:

To investigate the significance of drooling in adults with dermatomyositis and its association with advanced disease and complications.

Key Findings:
  • Drooling (sialorrhea) may indicate severe oropharyngeal muscle involvement in dermatomyositis.
  • All three patients experienced progressive disease and died despite intensive immunosuppressive therapy.
  • Aspiration pneumonia and sepsis were common complications.
  • Muscle biopsies showed severe pathologic changes, including atrophy and fibrosis.
  • Drooling has been rarely documented in dermatomyositis, contrasting with previously reported responsive cases.
Interpretation:

Drooling in dermatomyositis may signal advanced disease and a higher risk of life-threatening complications, necessitating aggressive treatment and careful monitoring.

Limitations:
  • The sample size is small, limiting generalizability.
  • Further studies are needed to establish a direct link between drooling and mortality risk.
Conclusion:

Drooling in dermatomyositis patients can indicate severe disease progression and warrants comprehensive evaluation and management.

Original Source(s)

Drooling Flags Severe Dermatomyositis

  • by Olivia Anderson

  • February 12, 2026

Related Content

Serum Urate Goals Tied to Lower CV Risk

Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients

Deep Remission Tied to RA Control

At 5 years, 63% of patients in the CliDR group maintained sustained remission compared with 38% in the non-CliDR group.

RA Prescribing Patterns Shift Over 15 Years

An aging Japanese cohort with rheumatoid arthritis saw increasing use of targeted synthetic therapies as glucocorticoid use declined.